High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge

The Purolite AP+50 affinity chromatography resin has a 50-micron bead size that offers dynamic binding capacity of the AP resin platform while providing durability for monoclonal antibody capture.

A continuous biomanufacturing platform can process higher/lower quantities of a drug as needed and allow manufacturers to respond to changing markets.

Although automation is increasingly adopted in biomanufacturing, challenges remain in implementing it at the cell harvesting step.

The benefits include reduced contamination risks, simplified validation processes, and streamlined operations.

Many factors must be considered to overcome the challenges associated with viral clearance.

Collaboration between technology providers and biopharma manufacturers are enabling both evolutionary and novel developments.